{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:40:41Z","timestamp":1780472441773,"version":"3.54.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>We report a 10-year-old boy with immunoglobulin (Ig)A vasculitis (IgAV) with prolonged cutaneous manifestations who was successfully treated with colchicine. At the age of 9 years, he was diagnosed as having IgAV by typical purpura, abdominal pain, and haematochezia. Initially, his severe gastrointestinal manifestation subsided by prednisolone 60\u2009mg\/day and intravenous methylprednisolone pulse therapy. However, his gastrointestinal manifestation was glucocorticoid-dependent and refractory to factor XIII concentrate, intravenous IgG, and mycophenolate mofetil. His abdominal pain and haematochezia responded to the combination therapy with dapsone and low dose of prednisolone 5\u2009mg\/day and did not relapse even after discontinuation of dapsone. On the other hand, the effect of dapsone on his cutaneous manifestation was dose-dependent as well as dapsone had no glucocorticoid-sparing effect. Approximately 12\u2009months after onset, colchicine treatment was started, which resulted in remission of his chronic cutaneous manifestation. After prednisolone was tapered off, his cutaneous manifestation is currently well-controlled on colchicine 0.5\u2009mg\/day without adverse events. He had never complicated kidney involvements. In conclusion, it is observed that colchicine treatment exerts a beneficial effect in IgAV patients with prolonged cutaneous manifestation refractory to multiple drugs.<\/jats:p>","DOI":"10.1093\/mrcr\/rxab041","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T13:49:44Z","timestamp":1635947384000},"page":"97-100","source":"Crossref","is-referenced-by-count":3,"title":["Successful treatment of IgA vasculitis with prolonged cutaneous manifestation with colchicine in a 10-year-old boy"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1050-2103","authenticated-orcid":false,"given":"Yuka","family":"Okura","sequence":"first","affiliation":[{"name":"Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Nawate","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"2022011123195511700_R1","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2019.00257","article-title":"Childhood IgA vasculitis (Henoch Schonlein purpura)-advances and knowledge gaps","volume":"7","author":"Oni","year":"2019","journal-title":"Front Pediatr"},{"key":"2022011123195511700_R2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0036933018809816","article-title":"Recurrent Henoch Schonlein purpura without renal involvement successfully treated with methotrexate","volume":"64","author":"Miray Kisla Ekinci","year":"2019","journal-title":"Scott Med J"},{"key":"2022011123195511700_R3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00431-020-03592-w","article-title":"Clinical outcome in pediatric refractory gastrointestinal Henoch-Schonlein purpura treated with mycophenolate mofetil","volume":"179","author":"Wang","year":"2020","journal-title":"Eur J Pediatr"},{"key":"2022011123195511700_R4","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-016-0100-x","article-title":"Azathioprine therapy for steroid-resistant Henoch-Schonlein purpura: a report of 6 cases","volume":"14","author":"Fotis","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"2022011123195511700_R5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3345\/kjp.2019.00514","article-title":"Treatment of refractory IgA vasculitis with dapsone: a systematic review","volume":"63","author":"Lee","year":"2020","journal-title":"Clin Exp Pediatr"},{"key":"2022011123195511700_R6","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00431-019-03409-5","article-title":"Indications and efficiency of dapsone in IgA vasculitis (Henoch-Schonlein purpura): case series and a review of the literature","volume":"178","author":"Roman","year":"2019","journal-title":"Eur J Pediatr"},{"key":"2022011123195511700_R7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14397595.2019.1687074","article-title":"Clinical manifestations and outcomes of 420 children with Henoch Schonlein purpura from a single referral center from Turkey: a three-year experience","volume":"30","author":"Ekinci","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2022011123195511700_R8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/0009922809337532","article-title":"Successful treatment of prolonged Henoch-Schonlein purpura with colchicine","volume":"48","author":"Saulsbury","year":"2009","journal-title":"Clin Pediatr (Phila)"},{"key":"2022011123195511700_R9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00431-015-2594-5","article-title":"Efficacy of colchicine in a child with relapsing bullous Henoch-Schonlein purpura","volume":"175","author":"Allali","year":"2016","journal-title":"Eur J Pediatr"},{"key":"2022011123195511700_R10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1525-1470.1999.99015.x","article-title":"Treatment of linear IgA bullous dermatosis of childhood with colchicine","volume":"16","author":"Ang","year":"1999","journal-title":"Pediatr Dermatol"},{"key":"2022011123195511700_R11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00005792-199911000-00005","article-title":"Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature","volume":"78","author":"Saulsbury","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"2022011123195511700_R12","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/jpc.12403","article-title":"Henoch-Schonlein purpura in children","volume":"49","author":"Trnka","year":"2013","journal-title":"J Paediatr Child Health"},{"key":"2022011123195511700_R13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/ard.2003.016196","article-title":"Sera from children with active Henoch-Schonlein purpura can enhance the production of interleukin 8 by human umbilical venous endothelial cells","volume":"63","author":"Yang","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2022011123195511700_R14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/014107688307600717","article-title":"Dapsone in allergic vasculitis: its use in Henoch-Schonlein disease following vaccination","volume":"76","author":"Ledermann","year":"1983","journal-title":"J R Soc Med"},{"key":"2022011123195511700_R15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulfones in dermatology: overview and update","volume":"45","author":"Zhu","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2022011123195511700_R16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/ijd.14761","article-title":"Update on the use of dapsone in dermatology","volume":"59","author":"Ghaoui","year":"2020","journal-title":"Int J Dermatol"},{"key":"2022011123195511700_R17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mehy.2017.07.018","article-title":"Dapsone as a potential treatment option for Henoch-Schonlein purpura (HSP)","volume":"108","author":"Lee","year":"2017","journal-title":"Med Hypotheses"},{"key":"2022011123195511700_R18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/1523-1747.ep12555654","article-title":"Dapsone suppresses integrin-mediated neutrophil adherence function","volume":"98","author":"Booth","year":"1992","journal-title":"J Invest Dermatol"},{"key":"2022011123195511700_R19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2249.2001.01503.x","article-title":"The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone","volume":"124","author":"Schmidt","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"2022011123195511700_R20","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl J Med"},{"key":"2022011123195511700_R21","first-page":"171","article-title":"Effect of dapsone on haemoglobin concentration in patients with leprosy","volume":"62","author":"Byrd","year":"1991","journal-title":"Lepr Rev"},{"key":"2022011123195511700_R22","first-page":"10","article-title":"Investigations into the haemolytic effects of dapsone therapy in leprosy patients","volume":"61","author":"Balakrishnan","year":"1989","journal-title":"Indian J Lepr"},{"key":"2022011123195511700_R23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjmed.2014.12.010","article-title":"Colchicine: old and new","volume":"128","author":"Slobodnick","year":"2015","journal-title":"Am J Med"},{"key":"2022011123195511700_R24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1189\/jlb.1012510","article-title":"Technical advance: inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments","volume":"94","author":"Paschke","year":"2013","journal-title":"J Leukoc Biol"},{"key":"2022011123195511700_R25","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1073\/pnas.74.8.3404","article-title":"Effects of colchicine on cyclic AMP levels in human leukocytes","volume":"74","author":"Rudolph","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011123195511700_R26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.15896","article-title":"Colchicine: an ancient drug with novel applications","volume":"178","author":"Dasgeb","year":"2018","journal-title":"Br J Dermatol"},{"key":"2022011123195511700_R27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/09546630500277971","article-title":"Management of leukocytoclastic vasculitis","volume":"16","author":"Sunderkotter","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"2022011123195511700_R28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0190-9622(85)70158-2","article-title":"Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis","volume":"13","author":"Callen","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"2022011123195511700_R29","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jpeds.2012.05.047","article-title":"Colchicine is a safe drug in children with familial Mediterranean fever","volume":"161","author":"Padeh","year":"2012","journal-title":"J Pediatr"},{"key":"2022011123195511700_R30","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s10067-019-04489-2","article-title":"MEFV gene mutations in children with Henoch-Schonlein purpura and their correlations-do mutations matter?","volume":"38","author":"Cakici","year":"2019","journal-title":"Clin Rheumatol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxab041\/41393473\/rxab041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/1\/97\/42106713\/rxab041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/1\/97\/42106713\/rxab041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:47:07Z","timestamp":1642560427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/6\/1\/97-100\/6420264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,3]]},"published-print":{"date-parts":[[2022,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxab041","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,11,3]]}}}